Evidence map›Paper›PMID 27539256›Full record

ReviewJournal of gastroenterology2017

Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.

Tetsuhide Ito, Susumu Hijioka, Toshihiko Masui, Atsuko Kasajima, Yuji Nakamoto, Noritoshi Kobayashi, Izumi Komoto, Masayuki Hijioka, Lingaku Lee, Hisato Igarashi and 2 more

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Tetsuhide ItoDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. itopapa@intmed3.med.kyushu-u.ac.jp.
Susumu HijiokaDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
Toshihiko MasuiDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Atsuko KasajimaDepartment of Pathology, Tohoku University Hospital, Sendai, Japan.
Yuji NakamotoDepartment of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Noritoshi KobayashiDepartment of Oncology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Izumi KomotoDepartment of Surgery, Kansai Electric Power Hospital, Osaka, Japan.
Masayuki HijiokaDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Lingaku LeeDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Hisato IgarashiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Robert Thomas JensenDigestive Diseases Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Masayuki ImamuraNeuroendocrine Tumor Center, Kansai Electric Power Hospital, Osaka, Japan.
Kyushu University · JPKansai Electric Power Hospital · JPKyoto University · JPAichi Cancer Center · JPNational Institutes of Health · USTohoku University Hospital · JPYokohama City University · JP

Funding

Diagnosis, Natural History, Management,tumor biology of Gastrinomas/PETs/Neuroendocrine tumorsZIADK053200 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JENSEN, ROBERT · 2009 to 2025
$4.3M
6 · The paper itself

Abstract

Several new developments have occurred in the field of pancreatic neuroendocrine neoplasm (PNEN) recently in Japan. First, the utility of chromogranin A (CgA), useful for the diagnosis and monitoring of the treatment response of neuroendocrine neoplasm (NEN), has been demonstrated in Japan. For PNEN diagnosis and treatment, grading and correct histological diagnosis according to the WHO 2010 classification is important. Regarding the histological diagnosis, the advent of endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) has enabled correct pathological diagnosis and suitable treatment for the affected tissue. Furthermore, EUS-FNA has also facilitates the assessment of the presence or absence of gene mutations. In addition, patients who have a well-differentiated neuroendocrine tumor (NET) showing a Ki-67 index of higher than 20 % according to the WHO 2010 classification, have also been identified, and their responses to treatment were found to be different from those of patients with poorly differentiated neuroendocrine carcinoma (NEC). Therefore, the concept of NET G3 was proposed. Additionally, somatostatin receptor type 2 is expressed in several cases of NET, and somatostatin receptor scintigraphy (

Indexed as

Chromogranin ACombined Modality TherapyEndoscopic Ultrasound-Guided Fine Needle AspirationHumansJapanNeoplasm GradingNeoplasm StagingNeuroendocrine TumorsPancreatic NeoplasmsPrognosisChromogranin A111In-octreoscanChromogranin AEUS-FNAMolecular target therapyNET G3Neuroendocrine tumorPancreatic neuroendocrine neoplasmSomatostatin receptor scintigraphyWHO classification

Identifiers

PMID27539256
OpenAlexW2511007377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.